Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Apr 14:6:24521.
doi: 10.1038/srep24521.

LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies

Ping Tan  1   2 , Shiyou Wei  3 , Zhuang Tang  1   2 , Liang Gao  1   2 , Chen Zhang  4 , Pan Nie  5 , Lu Yang  1   2 , Qiang Wei  1   2
Affiliations
Meta-Analysis

LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies

Ping Tan et al. Sci Rep. .

Abstract

The role of statins in preventing prostate cancer is currently a controversial issue. The aim of this review is to investigate the effects of statins use on prostate cancer risk. Electronic databases (the Cochrane Library, PubMed, Medline, Embase, Web of Science, and ClinicalTrials.gov) were searched systematically up to April, 2015. Weighted averages were reported as relative risk (RR) with 95% confidence intervals (CIs). Statistic heterogeneity scores were assessed with the standard Cochran's Q test and I(2) statistic. The pooled estimates of randomized controlled trials (RCTs) and retrospective studies suggest that statins have a neutral effect on total prostate cancer (RR = 1·02, 95% CI: 0·90-1·14; and RR = 0·91, 95% CI: 0·79-1·02, respectively). This research provides no evidence to suggest that the use of statins for cholesterol lowering is beneficial for the prevention of low-grade or localized prostate cancer, although a plausible association between statins use and the reduction risk of advanced (RR = 0·87, 95% CI: 0·82-0·91) or high-grade prostate cancer (RR = 0·83, 95% CI: 0·66-0·99) is observed. Furthermore, it shows that prostate cancer risk does not statistically significant benefit from long-term statins use.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Trial Identification, Inclusion, and Exclusion.
Figure 2
Figure 2. Statins use and risk of total prostate cancer in observational studies.
(From random-effects model, RR, relative risk; 95%CI, 95% confidence intervals).
Figure 3
Figure 3. Statins use and risk of total prostate cancer in 6 randomized controlled trials (From Fixed-effects model, RR, relative risk; 95%CI, 95% confidence intervals).
Figure 4
Figure 4. Statins use and risk of advanced prostate cancer (RR, relative risk; 95%CI, 95% confidence intervals).
Figure 5
Figure 5. Long-term statins use and risk of total prostate cancer (RR, relative risk; 95%CI, 95% confidence intervals).
Figure 6
Figure 6. Funnel plot for publication bias.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R., Ma J., Zou Z. & Jemal A. Cancer statistics. CA-Cancer J. Clin. 64, 9–29 (2014). - PubMed
    1. Carlberg M. et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J. Biol. Chem. 271, 17453–17462 (1996). - PubMed
    1. Wong W. W., Dimitroulakos J., Minden M. D. & Penn L. Z. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16, 508–519, 10.1038/sj.leu.2402476 (2002). - DOI - PubMed
    1. Jain M. K. & Ridker P. M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug. Discov. 4, 977–987 (2005). - PubMed
    1. Dulak J. & Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr. Cancer Drug Tar. 5, 579–594 (2005). - PMC - PubMed

Publication types

Substances